03 Sep 2026

CRC Research Update — September 03, 2026

Creator: The CRC Digest
Published: 2026-09-03T20:25:32Z

Today's colorectal cancer research highlights

2 min read

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

CRC Research Update

TREATMENT
Immunotherapy Compared to Standard Care in MSS Metastatic CRC
A propensity-matched analysis of 708 chemorefractory patients compared immune checkpoint inhibitors to standard treatments like trifluridine/tipiracil in microsatellite stable metastatic colorectal cancer, though ICIs have limited efficacy in this population and selected patients with specific metastatic patterns may derive benefit. (Journal for ImmunoTherapy of Cancer)
TREATMENT
Patients With Poor Performance Status Still Benefit From Immunotherapy in MSI-H CRC
An international retrospective study of dMMR/MSI-H metastatic colorectal cancer patients found that immune checkpoint blockers produced durable responses even in patients with poor ECOG performance status, a group often excluded from treatment. (Clinical Colorectal Cancer)
SCREENING
Computer-Aided Feedback System Evaluated for Colonoscopy Quality in Denmark
A stepped-wedge cluster-randomised trial across three Danish hospitals evaluated the effect of a computer-aided quality feedback and monitoring system on endoscopists' adenoma detection rate in patients aged 50-74 with positive FIT results. (The Lancet Digital Health)
TREATMENT
Real-World Data on Encorafenib Plus Panitumumab in BRAF V600E Metastatic CRC
A population-based multicenter study examined real-world outcomes of the targeted therapy combination encorafenib plus panitumumab in patients with BRAF V600E-mutated metastatic colorectal cancer. (Clinical Colorectal Cancer)

🔬 Under 50 Spotlight

Research relevant to early-onset and younger CRC patients

Screening Age Thresholds Miss Early-Onset CRC Risk Established in Youth
A new analysis argues that age-based screening creates a "blind spot" for early-onset colorectal cancer because high-risk states may be established through early-life exposures decades before screening begins at age 45. (Frontiers in Oncology)

🧬 Biomarker Spotlight

Research by genetic subtype — KRAS, BRAF, MSI-H, HER2, and more

HER2-Targeted Zanidatamab Produces Response in KRAS-Mutated Rectal Cancer
A case report describes a significant response in a 54-year-old male with HER2-amplified, KRAS G12D-mutated metastatic rectal cancer treated with a zanidatamab-based combination regimen. (Frontiers in Immunology)

Research continues to refine treatment strategies across molecular subtypes and improve early detection. Stay informed and discuss new findings with your care team.

Get CRC research intelligence delivered weekly — free.

Browse by Topic

KRAS Mutations Immunotherapy (MSI-H)BRAF Early-Onset / Under 50 Liver Metastases Clinical Trials Living with CRC All Issues

CRC Research Update

Subscribe to The CRC Digest